Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and lower dose) of RO5093151 administered twice daily (BID regimen) and RO5027838 administered once daily.

Trial Profile

Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and lower dose) of RO5093151 administered twice daily (BID regimen) and RO5027838 administered once daily.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs RG 4929 (Primary) ; RG 7234 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 07 Jun 2011 Results of an analysis that examined the effect of treatment on adrenal function was presented at the 93rd Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top